TORONTO, July 21 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the launch of ColonSentry(TM), the world's first blood-based molecular test for colorectal cancer screening. ColonSentry(TM) is a blood test that assesses a patient's current risk of having colorectal cancer, identifying those in the asymptomatic general population with increased risk who might benefit from further more invasive diagnostic testing such as colonoscopy. This risk stratification approach allows for a more targeted application of colonoscopy which could increase the detection rate of colorectal cancer by as much as 3 fold in an asymptomatic general population. The test requires a simple blood sample. The mRNA expression of a panel of seven specific genes is measured at the molecular level by quantitative RT-PCR which results in an assessment of the patient's current risk. ColonSentry will be performed at the Company's laboratory facilities in Richmond Hill, Canada and is the first in a series of blood-based molecular tests based on the company's platform technology, the award-winning Sentinel Principle(TM).
"Each year thousands of Canadians die from colorectal cancer, the
number two cause of death among all cancers in both men and women. This is
a tragedy because colorectal cancer is a preventable and curable disease,
but only when detected early," said Dr. Lawrence Cohen, Director of
Gastroenterology at Sunnybrook Health Sciences Centre and Associate
Professor of Medicine at the University of Toronto. "The launch of
ColonSentry(TM) represents a leap forward in the way we currently screen
for colorectal cancer. The test determines whether patients have an
increased risk of having colorectal cancer. By using this risk assessment
tool as the first step in a regular screening program, information obtained
with ColonSentry(TM) w
|SOURCE GeneNews Limited|
Copyright©2008 PR Newswire.
All rights reserved